跳轉至內容
Merck
全部照片(1)

重要文件

SML1958

Sigma-Aldrich

Bay 60-6583

≥98% (HPLC)

同義詞:

2-[[6-氨基-3,5-二氰基-4- [4-(环丙基甲氧基)苯基] -2-吡啶基]硫代]-乙酰胺, BAY606583, BR 4887, BR4887, Bay 60-6,583, Bay 606583

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C19H17N5O2S
CAS號碼:
分子量::
379.44
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

NC1=C(C#N)C(C2=CC=C(OCC3CC3)C=C2)=C(C#N)C(SCC(N)=O)=N1

InChI

1S/C19H17N5O2S/c20-7-14-17(12-3-5-13(6-4-12)26-9-11-1-2-11)15(8-21)19(24-18(14)23)27-10-16(22)25/h3-6,11H,1-2,9-10H2,(H2,22,25)(H2,23,24)

InChI 密鑰

ZTYHZMAZUWOXNC-UHFFFAOYSA-N

生化/生理作用

BAY 60-6583是一种有效的腺苷受体A2b(A2bR)的部分激动剂(抑制0.3 nM [3H] PSB-603与人/小鼠/大鼠A2bR结合的Ki = 114/136/100 nM),可在转染后表达人A2bR(EC50〜100 nM)的CHO中选择性诱导cAMP依赖性转录活性,但在表达A1R或A2aR的CHO中无效,其对人/大鼠/小鼠A2aR没有亲和力。BAY 60-6583还显示出对A1R(抑制1 nM [3H]CCPA与人/小鼠/大鼠A1R结合的 Ki= 387/351/514 nM;对100 nM CCPA诱导的hA1R β-抑制蛋白募集过程的抑制IC50 = 7.4 μM)和A3R(抑制10 nM [3H]NECA与人/小鼠/大鼠的A3R结合的 Ki= 223/3920/2750 nM;对30 nM Cl-IB-MECA诱导的hA3R β-抑制蛋白募集过程的抑制IC50 = 6.7 μM)的低亲和性拮抗活性。BAY 60-6583已通过i.p.(0.1-80 mg/kg)或i.v.(0.2-2 mg/kg)广泛应用于动物体内,以研究A2bR介导的生物反应。
对A1R & A3R具有低亲和力拮抗活性的有效腺苷受体A2bR部分激动剂。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Tobias Eckle et al.
Circulation, 115(12), 1581-1590 (2007-03-14)
Ecto-5'-nucleotidase (CD73)-dependent adenosine generation has been implicated in tissue protection during acute injury. Once generated, adenosine can activate cell-surface adenosine receptors (A1 AR, A2A AR, A2B AR, A3 AR). In the present study, we define the contribution of adenosine to
Atsushi Kuno et al.
Journal of molecular and cellular cardiology, 43(3), 262-271 (2007-07-17)
Although protein kinase C (PKC) plays a key role in ischemic preconditioning (IPC), the actual mechanism of that protection is unknown. We recently found that protection from IPC requires activation of adenosine receptors during early reperfusion. We, therefore, hypothesized that
Mohamad Wessam Alnouri et al.
Purinergic signalling, 11(3), 389-407 (2015-07-02)
Adenosine receptors (ARs) have emerged as new drug targets. The majority of data on affinity/potency and selectivity of AR ligands described in the literature has been obtained for the human species. However, preclinical studies are mostly performed in mouse or

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務